| Trial ID # | NCT04570839 |
| Phase | I/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PVRIG |
| Drug Name | COM701 |
| Drugs in Trial | BMS-986207, COM701, Nivolumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 20; median 4 prior therapies (1-10) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Efficacy | ORR: 20% (4PR - 3 HGSOC, 1 OCCC) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | The combination of COM701 + BMS-986207 + nivolumab is well tolerated and has encouraging durable anti-tumor activity with immune activation in patients with platinum resistant HGSOC and OCCC |
| Reference | Gaillard S et al. Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer. J Immunother Cancer (2023) 11: abstract 669 Gaillard S et al. Poster |